Cresset Asset Management, LLC Regenxbio Inc. Transaction History

Cresset Asset Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$12.17 - $24.61 $3,724 - $7,530	306 Added 1.76%	17,731 $373,000
Q4 2023 Feb 14, 2024	BUY	$12.89 - $20.82 $966 - $1,561	75 Added 0.43%	17,425 $312,000
Q3 2023 Nov 14, 2023	BUY	$16.46 - $19.99 $1,316 - $1,599	80 Added 0.46%	17,350 $285,000
Q2 2023 Aug 14, 2023	BUY	$17.23 - $21.71 $297,562 - $374,931	17,270 New	17,270 $345,000
Q1 2022 May 16, 2022	SELL	$24.62 - $34.31 $267,053 - $372,160	-10,847 Closed	0 $0
Q4 2021 Feb 10, 2022	BUY	$30.19 - $40.28 $327,470 - $436,917	10,847 New	10,847 $354,000
Q2 2019 Aug 12, 2019	SELL	$42.0 - $59.29 $2,562 - $3,616	-61 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$40.82 - $62.45 $2,490 - $3,809	61 New	61 $3,000

197

43.2M

104K

478K

Ticker RGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,230,000
Market Cap $439M
Description
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...

Get notified when there are updates to the investment portfolio of Cresset Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Cresset Asset Management, LLC with notifications on news.